Page 143 - Haematologica August 2018

Therapeutic effects of chidamide on myeloma-associated bone disease
lacking the integrin beta5 subunit have accelerated osteoclast maturation and increased activity in the estrogen-deficient state. J Bone Miner Res. 2005;20(1):58-66.
17. Paino T, Garcia-Gomez A, Gonzalez- Mendez L, et al. The Novel Pan-PIM Kinase Inhibitor, PIM447, Displays Dual Antimyeloma and Bone-Protective Effects, and Potently Synergizes with Current Standards of Care. Clin Cancer Res. 2017;23(1):225-238.
18. Tang J, Yan H, Zhuang S. Histone deacety- lases as targets for treatment of multiple dis- eases. Clin Sci (Lond). 2013;124(11):651-662.
19. Laubach JP, San-Miguel JF, Hungria V, et al. Deacetylase inhibitors: an advance in myeloma therapy? Expert Rev Hematol. 2017;10(3):229-237.
20. Seto E, Yoshida M. Erasers of histone acety- lation: the histone deacetylase enzymes. Cold Spring Harb Perspect Biol. 2014;6(4):a018713.
21. Pavithra L, Mukherjee S, Sreenath K, et al. SMAR1 forms a ternary complex with p53- MDM2 and negatively regulates p53-medi- ated transcription. J Mol Biol. 2009; 388(4):691-702.
22. Lesina M, Kurkowski MU, Ludes K, et al. Stat3/Socs3 activation by IL-6 transsignaling
promotes progression of pancreatic intraep- ithelial neoplasia and development of pan- creatic cancer. Cancer Cell. 2011;19(4):456- 469.
23. Siveen KS, Sikka S, Surana R, et al. Targeting the STAT3 signaling pathway in cancer: role of synthetic and natural inhibitors. Biochim Biophys Acta. 2014; 1845(2):136-154.
24. Liang P, Cheng SH, Cheng CK, et al. Platelet factor 4 induces cell apoptosis by inhibition of STAT3 via up-regulation of SOCS3 expression in multiple myeloma. Haematologica. 2013;98(2):288-295.
25. Ortega-Molina A, Boss IW, Canela A, et al. The histone lysine methyltransferase KMT2D sustains a gene expression program that represses B cell lymphoma develop- ment. Nat Med. 2015;21(10):1199-1208.
26. Hu Y, Benedict MA, Wu D, Inohara N, Nunez G. Bcl-XL interacts with Apaf-1 and inhibits Apaf-1-dependent caspase-9 activa- tion. Proc Natl Acad Sci USA. 1998;95(8):4386-4391.
27. Tan E, Weiss BM, Mena E, Korde N, Choyke PL, Landgren O. Current and future imaging modalities for multiple myeloma and its pre- cursor states. Leuk Lymphoma. 2011;52(9): 1630-1640.
28. Dotterweich J, Schlegelmilch K, Keller A, et
al. Contact of myeloma cells induces a char- acteristic transcriptome signature in skeletal precursor cells. Implications for myeloma bone disease. Bone. 2016;93:155-166.
29. Kawano Y, Moschetta M, Manier S, et al. Targeting the bone marrow microenviron- ment in multiple myeloma. Immunol Rev. 2015;263(1):160-172.
30. Cantley MD, Zannettino ACW, Bartold PM, Fairlie DP, Haynes DR. Histone deacetylases (HDAC) in physiological and pathological bone remodelling. Bone. 2017; 95:162-174.
31. Pham L, Kaiser B, Romsa A, et al. HDAC3 and HDAC7 have opposite effects on osteo- clast differentiation. J Biol Chem. 2011;286(14):12056-12065.
32. Blixt NC, Faulkner BK, Astleford K, et al. Class II and IV HDACs function as inhibitors of osteoclast differentiation. PLoS One. 2017;12(9):e0185441.
33. Sun W, Zhao C, Li Y, et al. Osteoclast- derived microRNA-containing exosomes selectively inhibit osteoblast activity. Cell Discov. 2016;2:16015.
34. Vallet S, Mukherjee S, Vaghela N, et al. Activin A promotes multiple myeloma- induced osteolysis and is a promising target for myeloma bone disease. Proc Natl Acad Sci USA. 2010;107(11):5124-5129.
haematologica | 2018; 103(8)
1379